Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort.
Granger LA, Huettner I, Debeljak F, Kaleebu P, Schechter M, Tambussi G, Weber J, Miro JM, Phillips R, Babiker A, Cooper DA, Fisher M, Ramjee G, Fidler S, Frater J, Fox J, Doores KJ. Granger LA, et al. Among authors: schechter m. AIDS. 2021 Nov 1;35(13):2073-2084. doi: 10.1097/QAD.0000000000002988. AIDS. 2021. PMID: 34127581 Free PMC article.
Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America.
Zhou J, Jaquet A, Bissagnene E, Musick B, Wools-Kaloustian K, Maxwell N, Boulle A, Wehbe F, Masys D, Iriondo-Perez J, Hemingway-Foday J, Law M; Western Africa, Eastern Africa, Southern Africa, Caribbean and Central and South America, and Asia Pacific Regions of the International Epidemiologic Databases to Evaluate AIDS-IeDEA. Zhou J, et al. J Int AIDS Soc. 2012 Jan 30;15(1):5. doi: 10.1186/1758-2652-15-5. J Int AIDS Soc. 2012. PMID: 22289654 Free PMC article.
Short-course antiretroviral therapy in primary HIV infection.
SPARTAC Trial Investigators; Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A. SPARTAC Trial Investigators, et al. Among authors: schechter m. N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039. N Engl J Med. 2013. PMID: 23323897 Free PMC article. Clinical Trial.
Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.
Stöhr W, Fidler S, McClure M, Weber J, Cooper D, Ramjee G, Kaleebu P, Tambussi G, Schechter M, Babiker A, Phillips RE, Porter K, Frater J. Stöhr W, et al. Among authors: schechter m. PLoS One. 2013 Oct 25;8(10):e78287. doi: 10.1371/journal.pone.0078287. eCollection 2013. PLoS One. 2013. PMID: 24205183 Free PMC article. Clinical Trial.
HIV-1 DNA predicts disease progression and post-treatment virological control.
Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators. Williams JP, et al. Among authors: schechter m. Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821. Elife. 2014. PMID: 25217531 Free PMC article.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
1,314 results